Alnylam has welcomed a draft decision from the National Institute for Health and Care Excellence (NICE) recommending the use of Amvuttra on the NHS in England.
The therapy – also known as vutrisiran – treats hereditary transthyretin-related (ATTRv) amyloidosis. It comes in the form of a subcutaneous injection administered once every three months and aims to address the root cause of ATTRv amyloidosis by reducing the production of the abnormal protein…
